These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 33369635)

  • 1. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
    Nielsen TO; Leung SCY; Rimm DL; Dodson A; Acs B; Badve S; Denkert C; Ellis MJ; Fineberg S; Flowers M; Kreipe HH; Laenkholm AV; Pan H; Penault-Llorca FM; Polley MY; Salgado R; Smith IE; Sugie T; Bartlett JMS; McShane LM; Dowsett M; Hayes DF
    J Natl Cancer Inst; 2021 Jul; 113(7):808-819. PubMed ID: 33369635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.
    Faragalla H; Plotkin A; Barnes P; Lu FI; Kos Z; Mulligan AM; Bane A; Nofech Mozes S
    Curr Oncol; 2023 Mar; 30(3):3079-3090. PubMed ID: 36975446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system.
    Shim VC; Baker RJ; Jing W; Puentes R; Agersborg SS; Lee TK; GoreaI W; Achacoso N; Lee C; Villasenor M; Lin A; Kapali M; Habel LA
    Breast Cancer Res Treat; 2024 Jan; 203(2):281-289. PubMed ID: 37847456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment.
    Eshwaraiah MS; Gunda A; Kanakasetty GB; Bakre MM
    Cancer Med; 2023 Jun; 12(12):13342-13351. PubMed ID: 37245224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer.
    Arun I; Venkatesh S; Ahmed R; Agrawal SK; Leung SCY
    APMIS; 2021 Aug; 129(8):489-502. PubMed ID: 34053140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
    Dowsett M; Nielsen TO; A'Hern R; Bartlett J; Coombes RC; Cuzick J; Ellis M; Henry NL; Hugh JC; Lively T; McShane L; Paik S; Penault-Llorca F; Prudkin L; Regan M; Salter J; Sotiriou C; Smith IE; Viale G; Zujewski JA; Hayes DF;
    J Natl Cancer Inst; 2011 Nov; 103(22):1656-64. PubMed ID: 21960707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 assessment in breast cancer: an update.
    Penault-Llorca F; Radosevic-Robin N
    Pathology; 2017 Feb; 49(2):166-171. PubMed ID: 28065411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group.
    Boyaci C; Sun W; Robertson S; Acs B; Hartman J
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
    Guiu S; Michiels S; André F; Cortes J; Denkert C; Di Leo A; Hennessy BT; Sorlie T; Sotiriou C; Turner N; Van de Vijver M; Viale G; Loi S; Reis-Filho JS
    Ann Oncol; 2012 Dec; 23(12):2997-3006. PubMed ID: 23166150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
    Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Ikeda K; Ogawa Y; Ishikawa T; Hirakawa K
    Breast Cancer Res; 2011; 13(6):R122. PubMed ID: 22126395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Zhang A; Wang X; Fan C; Mao X
    Front Endocrinol (Lausanne); 2021; 12():687244. PubMed ID: 34803903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial.
    Nielsen TO; Leung SCY; Riaz N; Mulligan AM; Kos Z; Bane A; Whelan TJ
    Histopathology; 2023 Dec; 83(6):903-911. PubMed ID: 37609778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
    Leung SCY; Nielsen TO; Zabaglo LA; Arun I; Badve SS; Bane AL; Bartlett JMS; Borgquist S; Chang MC; Dodson A; Ehinger A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hugh JC; Kos Z; Laenkholm AV; Mastropasqua MG; Moriya T; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Sakatani T; Salgado R; Starczynski J; Sugie T; van der Vegt B; Viale G; Hayes DF; McShane LM; Dowsett M;
    Histopathology; 2019 Aug; 75(2):225-235. PubMed ID: 31017314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, assessment and significance of Ki67 expression in breast cancer: an update.
    Lashen AG; Toss MS; Ghannam SF; Makhlouf S; Green A; Mongan NP; Rakha E
    J Clin Pathol; 2023 Jun; 76(6):357-364. PubMed ID: 36813558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.